Full Paper
Lamellarins as Inhibitors of P-Glycoprotein-Mediated Multidrug Resistance in a Human Colon Cancer Cell Line
Article first published online: 30 MAR 2012
DOI: 10.1002/asia.201101049
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Additional Information
How to Cite
Plisson, F., Huang, X.-C., Zhang, H., Khalil, Z. and Capon, R. J. (2012), Lamellarins as Inhibitors of P-Glycoprotein-Mediated Multidrug Resistance in a Human Colon Cancer Cell Line. Chem. Asian J., 7: 1616–1623. doi: 10.1002/asia.201101049
Publication History
- Issue published online: 14 JUN 2012
- Article first published online: 30 MAR 2012
- Manuscript Revised: 14 FEB 2012
- Manuscript Received: 24 DEC 2011
Funded by
- Australian Research Council. Grant Number: ARC LP0775547
- Noscira
Keywords:
- cancer;
- inhibitor;
- lamellarin;
- multidrug resistance;
- p-glycoprotein
Abstract
Chemical analysis of a Didemnum sp. (CMB-01656) collected during scientific Scuba operations off Wasp Island, New South Wales, yielded five new lamellarins A1 (1), A2 (2), A3 (3), A4 (4) and A5 (5) and eight known lamellarins C (6), E (7), K (8), M (9), S (10), T (11), X (12) and χ (13). Analysis of a second Didemnum sp. (CMB-02127) collected during scientific trawling operations along the Northern Rottnest Shelf, Western Australia, yielded the new lamellarin A6 (14) and two known lamellarins G (15) and Z (16). Structures were assigned to 1–16 on the basis of detailed spectroscopic analysis with comparison to literature data and authentic samples. Access to this unique library of natural lamellarins (1–16) provided a rare opportunity for structure–activity relationship (SAR) investigations, probing interactions between lamellarins and the ABC transporter efflux pump P-glycoprotein (P-gp) with a view to reversing multidrug resistance in a human colon cancer cell line (SW620 Ad300). These SAR studies, which were expanded to include the permethylated lamellarin derivative (17) and a series of lamellarin-inspired synthetic coumarins (19–24) and isoquinolines (25–26), successfully revealed 17 as a promising new non-cytotoxic P-gp inhibitor pharmacophore.

1861-471X/asset/2451_left.gif?v=1&s=879804fa8b46cf0a7c9ada963b3a3d8b5e4c5a21)
1861-471X/asset/olbannercenter.gif?v=1&s=168589aa4ee06245869d9ebf5e050019ec1c9da7)
1861-471X/asset/2451_right.gif?v=1&s=7e39970753c72792f9c3045b7c65df3b29c1b6a0)
